Physician

Oncology

Dr. Daniel Y. Heng, MD

Dr. Daniel Y. Heng works in the field of Oncology. Daniel Y. Heng is also a published doctor. He has 36 publication published. The most recent publication is: Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.

Publications

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma p...
Combination therapy in metastatic renal cell carcinoma.
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Re: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized cl...
Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Hypertension, concurrent cardiovascular risk factors and mortality: the Singapore Cardiovascular Cohort Study.
Screening for diabetes mellitus--a two-step approach in individuals with impaired fasting glucose improves detection of those at risk of complications.
The relevance of oncogenes as prognostic markers in cervical cancer.
Predictors of axillary lymph node metastases in women with early breast cancer in Singapore.
Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
Deep vein thrombosis is not rare in Asia--the Singapore General Hospital experience.
Longitudinal study of the socio-demographic determinants of changes in body weight and waist circumference in a multi-ethnic Asian population.
Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma.
State-of-the-art treatment of metastatic renal cell carcinoma.
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Sunitinib.
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from ...
Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer.
Non-clear cell renal cancer: features and medical management.
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vas...
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Prognostic and predictive biomarkers in renal cell carcinoma.
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib.
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.
Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Nathan E. Langer, MD This Doctor is OpenDoctor Recommended.
	Dr. Peter J. Oppelt, MD This Doctor is OpenDoctor Recommended.
	Dr. Lindsey M. Goodman, MD This Doctor is OpenDoctor Recommended.
	Dr. Paula Silverman, MD This Doctor is OpenDoctor Recommended.
	Dr. Bassam N. Estfan, MD This Doctor is OpenDoctor Recommended.
	Dr. Ming Zhou, MD This Doctor is OpenDoctor Recommended.
	Dr. Dale H. Cowan, MD This Doctor is OpenDoctor Recommended.
	Dr. Manmeet S. Ahluwalia, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Cheng E. Chee, MD This Doctor is OpenDoctor Recommended.
	Dr. Joseph A. Bokar, MD This Doctor is OpenDoctor Recommended.